SELLAS Life Sciences GroupSLS -6.94%25 Cash Ratio is 16.59 as of Mar. 2026, which is 1120% above its 10-year median of 1.36. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,388 Biotechnology companies, SELLAS Life Sciences Group ranks better than 90.42% on this metric.
SELLAS Life Sciences Group has a Cash Ratio of 16.59. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for SELLAS Life Sciences Group's Cash Ratio or its related term are showing as below:
SLS'
s Cash Ratio Range Over the Past 10 Years
Min: 0.05 Med: 1.36 Max: 16.59
Current: 16.59
During the past 13 years, SELLAS Life Sciences Group's highest Cash Ratio was 16.59. The lowest was 0.05. And the median was 1.36.
SLS's Cash Ratio is ranked better than 90.42% of 1388
companies
in the Biotechnology industry
Industry Median: 2.93
vs SLS: 16.59
SELLAS Life Sciences Group (NAS:SLS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
SELLAS Life Sciences Group Cash Ratio Related Terms
SELLAS Life Sciences Group Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SELLAS Life Sciences Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Cash Ratio distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (SLS) has a Cash Ratio of 16.59 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on SELLAS Life Sciences Group and its competitors. This is 1120% above median its historical median of 1.36. Over the past decade, SELLAS Life Sciences Group's Cash Ratio has ranged from 0.05 to 16.59. According to the industry distribution chart, SELLAS Life Sciences Group ranks #133 out of 1388 companies in the Biotechnology industry, placing it in the top 9.6%.
Is SELLAS Life Sciences Group's Cash Ratio too high?
SELLAS Life Sciences Group's current Cash Ratio of 16.59 is 1120% above median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 16.59. The Biotechnology industry median Cash Ratio is 2.93. SELLAS Life Sciences Group's value of 16.59 is 466.2% above this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #133 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Cash Ratio compare to MBX and BHVN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #133 out of 1388 companies for Cash Ratio. This places SELLAS Life Sciences Group in the top 10% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. SELLAS Life Sciences Group's value of 16.59 is 466.2% above this benchmark. Historically, SELLAS Life Sciences Group's own Cash Ratio has ranged from 0.05 to 16.59 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 2.93, SELLAS Life Sciences Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current Cash Ratio of 16.59 is 466.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current Cash Ratio is 16.59, which is 1120% above median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Cash Ratio of 16.59. The current Cash Ratio is 16.59, which is 1120% above median its 10-year median of 1.36 and 466.2% above the Biotechnology industry median of 2.93. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Cash Ratio is 16.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
